This HTML5 document contains 165 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n8http://dx.doi.org/10.1080/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q31142213
rdf:type
wikibase:Item
schema:description
bài báo khoa học 2016年论文 2016年論文 บทความทางวิทยาศาสตร์ tudományos cikk wissenschaftlicher Artikel научная статья 2016 թվականի նոյեմբերին հրատարակված գիտական հոդված мақолаи илмӣ artigo científico (publicado na 2016) artigo científico (publicado na 2016) wetenschappelijk artikel artikulong pang-agham bilimsel makale 2016年の論文 naučni članak مقالهٔ علمی vědecký článek 2016年论文 vedecký článok სამეცნიერო სტატია ২০১৬-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ vitskapeleg artikkel articolo scientifico научна статия artículo científico publicado en 2016 2016年论文 videnskabelig artikel (udgivet 2016) מאמר מדעי artikull shkencor artykuł naukowy 2016年论文 наукова стаття, опублікована в листопаді 2016 2016年論文 2016년 논문 2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած 2016年論文 مقالة علمية (نشرت في 14-11-2016) 2016 nî lūn-bûn vitenskapelig artikkel scientific article artigo científico научни чланак επιστημονικό άρθρο vetenskaplig artikel научни чланак articol științific tieteellinen artikkeli سائنسی مضمون mokslinis straipsnis мақолаи илмӣ article scientifique (publié 2016) 2016年論文 2016年论文 2016年论文 article scientific artículu científicu espublizáu en 2016 article científic teaduslik artikkel scienca artikolo 2016年論文
p:P577
wds:Q31142213-6C29453B-BE02-4ECD-9621-5791E5CD103C
wdt:P577
2016-11-14T00:00:00Z
p:P407
wds:Q31142213-DA8DC53D-C811-4894-BFE4-58860582B55C
wdt:P407
wd:Q1860
p:P2860
wds:Q31142213-E3B41EC8-4C95-409B-A4CC-51F102729496 wds:Q31142213-F2E32E68-C95D-4C8D-B0F3-70200C1B4D9B wds:Q31142213-F7D3B3AA-C6E8-4FE4-8522-BCBAEC73C698 wds:Q31142213-82C55103-BB8A-4471-BDA9-9F770A3C1169 wds:Q31142213-A62BE672-8A53-48D3-9100-B925DBFDC966 wds:Q31142213-AB587256-F967-488E-ABE6-54054FD75228 wds:Q31142213-C450B40D-0BDE-4C58-BC22-FCB1F8CA480A wds:Q31142213-D0401F2F-BE83-48B7-9B4B-B89F6D94B837 wds:Q31142213-4C6D2155-4B00-41EE-BC7A-D4C1871940CE wds:Q31142213-4F3F8E59-486F-474A-85F2-BF014BF53BDD wds:Q31142213-50E0361D-B7D2-42F8-9A66-9A31B294E70F wds:Q31142213-5E7497B8-3417-498E-9D4D-1258F29D0191 wds:Q31142213-6F1C20A1-0654-479D-87E8-209AFBC1AAD1 wds:Q31142213-6F4FB5D7-58F1-4CE7-BA0E-04D38C0868AB wds:Q31142213-78C6397D-71E1-4423-8A04-789FB0329E09 wds:Q31142213-7C728963-E6B9-4136-B0F6-4060F5807F89 wds:Q31142213-800016B5-1BD9-4B2E-82BE-EA32D7E3B884 wds:Q31142213-00DB2CD3-95DF-476E-A4E4-8E27D2FECCED wds:Q31142213-0DB2AD99-E8F5-4E72-A043-90B65E6FA2D5 wds:Q31142213-11F35F4F-B7CA-44A6-8B24-E8DC307D867C wds:Q31142213-27264593-E967-4771-B207-718CD6345E01 wds:Q31142213-2837A368-9F8D-4B22-83AD-57C793555A3B wds:Q31142213-2DF5E755-6160-4DA0-9436-8AC598050919 wds:Q31142213-43DFF217-3F70-41A2-9686-DF6E19500B74
wdt:P2860
wd:Q38091730 wd:Q36400944 wd:Q37240851 wd:Q38112200 wd:Q46035621 wd:Q34183674 wd:Q38007053 wd:Q28246204 wd:Q57938017 wd:Q33375283 wd:Q33581197 wd:Q29542197 wd:Q56390566 wd:Q38478174 wd:Q53730492 wd:Q55933838 wd:Q38404422 wd:Q45259565 wd:Q41899882 wd:Q34260552 wd:Q45113883 wd:Q38196495 wd:Q37163550 wd:Q37025987
p:P2093
wds:Q31142213-06F6C984-D01B-4713-AB8F-164DCD9A7E4E wds:Q31142213-57FF38A4-B98E-4111-B259-D13C40FB06DD wds:Q31142213-4B31C4C5-76D6-4248-8DBC-1B77C1C72DF1 wds:Q31142213-60B2E0F2-806B-40DA-B03D-C30F3688AEC4 wds:Q31142213-E18AB26E-5BEA-4CFC-B6E8-44BD925491E6 wds:Q31142213-D375FC5F-500D-4061-84C7-0B9BB79D26EC wds:Q31142213-CB77152D-13B2-433D-9B0A-8A5770EF8499
wdt:P2093
Lei Chen George Joseph Todor Totev Xi Yang Nanxin Li Liangyi Fan Subrata Bhattacharyya
rdfs:label
Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data
skos:prefLabel
Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data
schema:name
Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data
p:P50
wds:Q31142213-0795CDED-D44B-4715-BE85-45504913684B
wdt:P50
wd:Q67190838
p:P1476
wds:Q31142213-5254F1EC-9B87-409E-8759-EB21AF3EDF05
wdt:P1476
Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data
p:P304
wds:Q31142213-916103EB-E31F-4214-88BC-D91E1F2FCCA8
wdt:P304
328-336
p:P31
wds:Q31142213-4F84688C-C1C0-4AA7-B102-94425956D8AD
wdt:P31
wd:Q13442814
p:P921
wds:Q31142213-40CF6BF3-7C0A-4D1B-8C05-5D882D6D3ED3 wds:Q31142213-D30EC8F1-8582-4A3D-BA32-E9F32C1E216C wds:Q31142213-B9FEE9DA-3BF4-459A-9C13-28C4E539D542 wds:Q31142213-C19A2025-FA1E-46D0-A122-1FE905FE300F
wdt:P921
wd:Q27139135 wd:Q177094 wd:Q419940 wd:Q729735
p:P698
wds:Q31142213-3614B0B2-8559-45BA-906E-B03FD8E841E8
wdtn:P698
n12:27841717
wdt:P698
27841717
p:P1433
wds:Q31142213-A06F3FA7-F87D-4324-8025-45FA776BED43
wdt:P1433
wd:Q6295521
p:P433
wds:Q31142213-44F0EC3F-29E0-4F31-B823-47A79792FAAA
p:P478
wds:Q31142213-8368AB90-FA76-4300-9F23-ACBD51C856B8
wdt:P433
4
wdt:P478
20
p:P356
wds:Q31142213-D712C472-8BA3-4357-A753-24C7A156641D
wdtn:P356
n8:13696998.2016.1261032
wdt:P356
10.1080/13696998.2016.1261032